Logo image
Long-term Skeletal Muscle Protection After Gene Transfer in a Mouse Model of LGMD-2D
Journal article   Open access   Peer reviewed

Long-term Skeletal Muscle Protection After Gene Transfer in a Mouse Model of LGMD-2D

Christina A Pacak, Glenn A Walter, Gabe Gaidosh, Nathan Bryant, Melissa A Lewis, Sean Germain, Cathryn S Mah, Kevin P Campbell and Barry J Byrne
Molecular therapy, Vol.15(10), pp.1775-1781
10/2007
DOI: 10.1038/sj.mt.6300246
PMID: 17653106
url
https://doi.org/10.1038/sj.mt.6300246View
Published (Version of record) Open Access

Abstract

Limb girdle muscular dystrophy (LGMD) describes a group of inherited diseases resulting from mutations in genes encoding proteins involved in maintaining skeletal muscle membrane stability. LGMD type-2D is caused by mutations in alpha-sarcoglycan (sgca). Here we describe muscle-specific gene delivery of the human sgca gene into dystrophic muscle using an adeno-associated virus 1 (AAV1) capsid and creatine kinase promoter. Delivery of this construct to adult sgca–/– mice resulted in localization of the sarcoglycan complex to the sarcolemma and a reduction in muscle fiber damage. Sgca expression prevented disease progression as observed in vivo by T2-weighted magnetic resonance imaging (MRI) and confirmed in vitro by decreased Evan's blue dye accumulation. The ability of recombinant AAV–mediated gene delivery to restore normal muscle mechanical properties in sgca–/– mice was verified by in vitro force mechanics on isolated extensor digitorum longus (EDL) muscles, with a decrease in passive resistance to stretch as compared with untreated controls. In summary, AAV/AAV-sgca gene transfer provides long-term muscle protection from LGMD and can be non-invasively evaluated using magnetic resonance imaging.

Details

Metrics

Logo image